MVB Financial Reports Q4 Earnings Results
- Earnings Per Share: MVB Financial reported a GAAP EPS of $0.32 for Q4, indicating stable profitability amidst a complex market environment, which may attract investor interest.
- Revenue Growth: The company achieved revenue of $39.08 million in Q4, reflecting a year-over-year increase that highlights positive trends in business expansion and market demand.
- Financial Health: MVB Financial's financial data suggests a good balance between cost control and revenue enhancement, laying a solid foundation for future investments and growth opportunities.
- Dividend Performance: The dividend scorecard for MVB Financial underscores its commitment to shareholder returns, further boosting investor confidence in the company's long-term prospects.
Trade with 70% Backtested Accuracy
Analyst Views on MVBF
About MVBF
About the author

- Quarterly Cash Dividend: MVB Financial Corp. has declared a cash dividend of $0.17 per share, consistent with the previous quarter, indicating the company's stable financial position and commitment to shareholder returns.
- Dividend Payment Date: The dividend will be payable on March 15, 2026, for shareholders of record as of March 1, 2026, ensuring timely returns for investors and bolstering investor confidence.
- Strong Business Momentum: CEO Larry F. Mazza noted that MVB delivered solid fourth-quarter results for 2025, demonstrating significant progress in strategic execution and profitability enhancement.
- Future Outlook: MVB Financial is focused on enhancing profitability, which is expected to lay a solid foundation for business growth in 2026 and beyond, reflecting the company's positive outlook on future market opportunities.
- Board Leadership Change: MVB Financial Corp. has appointed Dr. Kelly R. Nelson as the new Chairman of the Board, succeeding the retiring W. Marston Becker; Nelson, a board member since 2004, brings extensive medical and business expertise that is expected to enhance corporate governance and compliance.
- New Board Member: Adam Famularo joins the Board, bringing extensive experience in financial technology and artificial intelligence, having served as CEO of WorkFusion; his strategic insights are anticipated to guide MVB through the evolving financial landscape.
- Community Engagement and Expertise: Dr. Nelson's strong medical background and leadership at MedExpress provide a unique advantage in fostering community ties, which may enhance MVB's trust and brand image among clients.
- Future Growth Outlook: Famularo's addition aligns with MVB's growth strategy, as his expertise in financial crime compliance is expected to support the company's sustainable development in a highly competitive market.
- Earnings Per Share: MVB Financial reported a GAAP EPS of $0.32 for Q4, indicating stable profitability amidst a complex market environment, which may attract investor interest.
- Revenue Growth: The company achieved revenue of $39.08 million in Q4, reflecting a year-over-year increase that highlights positive trends in business expansion and market demand.
- Financial Health: MVB Financial's financial data suggests a good balance between cost control and revenue enhancement, laying a solid foundation for future investments and growth opportunities.
- Dividend Performance: The dividend scorecard for MVB Financial underscores its commitment to shareholder returns, further boosting investor confidence in the company's long-term prospects.
- Net Income Growth: MVB Financial reported a net income of $4.2 million for Q4 2025, translating to $0.33 per basic share, reflecting the company's strong performance in the fintech sector and solidifying its market position.
- Interest Income Increase: Net interest income rose by 6.8% to $28.4 million, with the net interest margin expanding to 3.70%, indicating effective management of loan and deposit operations that enhances profitability.
- Strong Loan Growth: The company experienced a loan growth rate of 3.7%, with noninterest-bearing deposits making up 40.3% of total deposits, which not only reflects customer trust in MVB Bank's services but also lays a foundation for future business expansion.
- Strategic Investment Success: The successful sale of the Victor project provided capital flexibility, supporting the company's fintech incubator strategy, which is expected to further drive growth and profitability into 2026.
Recognition for Company Culture: MVB Bank, Inc. has received five accolades in 2025 for its strong workplace culture and employee satisfaction, including a sixth-place ranking on American Banker's Best Banks to Work For list.
Commitment to Employee Experience: The bank has been certified as a Great Place to Work for four consecutive years, highlighting its dedication to employee experience through initiatives that promote work-life balance, professional growth, and wellness.
Awards for Diversity and Inclusion: MVB was recognized as one of the Best Places to Work for Women and Best Places to Work in West Virginia, showcasing its commitment to equity, opportunity, and retention of female talent.
Focus on Employee Satisfaction: The awards assess various factors such as corporate culture, development opportunities, pay and benefits, and leadership satisfaction, reflecting MVB's efforts to create a supportive and empowering work environment.
Stock Repurchase Program Announcement: MVB Financial Corp. has authorized a stock repurchase program of up to $10 million, set to begin in November 2025, with purchases made through various means as determined by management.
Confidence in Financial Strength: CEO Larry F. Mazza highlighted the company's strong capital position and confidence in its balance sheet, following the successful completion of a previous $10 million repurchase program in May 2025.
Company Overview: MVB Financial Corp. is the holding company for MVB Bank, Inc., publicly traded on Nasdaq under the ticker "MVBF," providing financial services in the Mid-Atlantic region and beyond.
Forward-Looking Statements Disclaimer: The company has issued forward-looking statements regarding future operations, emphasizing the risks and uncertainties that could affect actual results, and advises against undue reliance on these statements.








